Latest Capital Strategy News

Scout Security reported a significant 62% reduction in operating cash outflows for Q3 FY2025, while advancing a potential acquisition and partnership opportunities following CES. The company’s cash position remains tight, prompting ongoing capital raising efforts.

EBOS Group Limited has updated its final dividend details for the six months ending June 2025, confirming a fully franked ordinary dividend and specifying the Dividend Reinvestment Plan strike price.

Shine Justice Ltd has announced an on-market buy-back of up to 10% of its ordinary shares, set to begin in October 2025 and run for a year. This move signals a strategic capital management initiative without requiring shareholder approval.

Commonwealth Bank of Australia announces a fully franked quarterly dividend of AUD 1.1222 per PERLS XV capital note, payable in December 2025, reflecting steady income for investors.

Commonwealth Bank of Australia announces a fully franked dividend of AUD 1.1047 per security on its PERLS XIV capital notes for the quarter ending December 2025, with payment scheduled for mid-December.

Alice Queen Limited has raised $1 million through convertible notes to fund ongoing gold and copper exploration and support working capital needs.

Enova Mining has narrowed its half-year loss to $1.07 million while progressing key rare earth and lithium projects in Brazil and Australia, supported by recent capital raises totaling $2.35 million.

Light & Wonder, Inc. has announced a proposed $1 billion private offering of senior unsecured notes due 2033, aiming to refinance existing debt and support corporate initiatives.

Pengana International Equities Limited has announced an on-market buy-back of up to 25.7 million ordinary shares, signaling a strategic capital management move without requiring shareholder approval.

Adelong Gold has locked in a $1.25 million strategic investment from Nova Minerals and Barclay Wells clients, enabling accelerated exploration at its NSW and Victorian gold and antimony projects. This partnership includes board representation and offtake rights, positioning Adelong for growth in proven mineral corridors.

The Alternative Investment Trust (AIQ) has extended its on-market buy-back of up to 10% of issued units, signaling continued capital management efforts amid steady market conditions.

Botanix Pharmaceuticals posted a sharp revenue increase driven by its new hyperhidrosis treatment Sofdra, yet reported a substantial net loss reflecting heavy investment in commercialisation. The company’s strong cash position underpins its path to profitability.